(RTTNews) - Newron Pharmaceuticals (NP5.DE) said the FDA has provided written feedback regarding the clinical hold affecting U.S. sites in its Phase 3 ENIGMA-TRS 2 study of evenamide, and the company is preparing a response.
我们公开展示核心要点。创建免费账户后可继续阅读全文、保存、讨论，并结合市场和 OSINT 背景分析。